ClinicalTrials.gov Protocol and Results Registration System (PRS) Receipt
Release Date: 06/22/2011

ClinicalTrials.gov ID: NCT00748982

Study Identification

Unique Protocol ID:	D3190C00013
Brief Title:	Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
Official Title:	A Single-centre, Single-blind, Randomised, Placebo-controlled Phase IIa Study to Investigate the Effect of AZD1305 Given as an Intravenous (iv) Infusion on Left Ventricular Performance in Patients With Left Ventricular Dysfunction
Secondary IDs:	2008-001254-41

Study Status

Record Verification:	June 2011
Overall Status:	Completed
Study Start:	August 2008
Primary Completion:	July 2009 [Actual]
Study Completion:	July 2009 [Actual]

Sponsor/Collaborators

Sponsor:	AstraZeneca
Responsible Party:	
Collaborators:	

Oversight

FDA Regulated?:	Yes
Applicable Trial?:	Section 801 Clinical Trial? Yes

	Delayed Posting? No
IND/IDE Protocol?:	No
Review Board:	Approval Status: Approved Approval Number: 324-08 Board Name: Regional Ethics Committee in Gothenburg, Sweden Board Affiliation: Regional Ethics Committee in Gothenburg, Sweden Phone: +46 (0) 31 786 68 22 Email: inger.hellstrom@gu.se
Data Monitoring?:	No
Plan to Share Data?:	
Oversight Authorities:	Sweden: Medical Products Agency

Study Description

Brief Summary:	To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction
Detailed Description:	

Conditions

Conditions:	Left Ventricle Function
Keywords:	AZD1305 anti-arrhythmics safety

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 2
Intervention Model:	Parallel Assignment
Number of Arms:	2
Masking:	Single Blind (Subject)
Allocation:	Randomized
Endpoint Classification:	Safety Study

Enrollment: 16 [Actual]

Arms and Interventions

Arms	Assigned Interventions
Experimental: 1	Drug: AZD1305 iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Placebo Comparator: 2	Drug: Placebo iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes

Outcome Measures

[See Results Section.]

Eligibility

Minimum Age: 20 Years

Maximum Age: 80 Years

Gender: Both

Accepts Healthy Volunteers?: No

Criteria: Inclusion Criteria:

- Male patients and postmenopausal women
- Mildly/moderately decreased heart function
- Regular heart rhythm

Exclusion Criteria:

- Potassium outside normal reference values
- Child bearing potential
- Severely decreased heart function

Contacts/Locations

Study Officials: Helen Lund, MD
Study Director
AstraZeneca R&D Mölndal, Sweden

Marianne Hartford, MD

Study Principal Investigator
AstraZeneca, Clinical Pharmacology Unit at Sahlgrenska University Hospital, Sweden

Locations: Sweden
Research Site
Goteborg, Sweden

References

Citations:

Links:

Study Data/Documents:

Study Results

Participant Flow

Recruitment Details	The study enrolled 33 patients and randomised 16 patients between August 2008 and July 2009 at a Clinical Pharmacology Unit located at a University Hospital in Sweden.
Pre-Assignment Details	Screening for eligibility and no significant changes in the medication for heart failure during the preceding 1 month before enrolment. In addition, patients for whom it was not possible to obtain high quality echocardiographic pictures were excluded from the study. The pre-entry visit was 30 days or less before the first dosing visit.

Reporting Groups

	Description
AZD1305 Dose 1 and Dose 2	AZD1305 was given as an initial intravenous (iv) loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out. The mean total dose of AZD1305 was 30 mg (range 29-31 mg)
Placebo Dose 1 and Dose 2	Sodium chloride was given as an initial iv loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out

Overall Study

	AZD1305 Dose 1 and Dose 2	Placebo Dose 1 and Dose 2
Started	12	4
Completed	12	4
Not Completed	0	0

Baseline Characteristics

Reporting Groups

	Description
AZD1305 Dose 1 and Dose 2	AZD1305 was given as an initial intravenous (iv) loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out. The mean total dose of AZD1305 was 30 mg (range 29-31 mg)
Placebo Dose 1 and Dose 2	Sodium chloride was given as an initial iv loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out

Baseline Measures

	AZD1305 Dose 1 and Dose 2	Placebo Dose 1 and Dose 2	Total
Number of Participants	12	4	16
Age, Continuous [units: Years] Mean (Standard Deviation)	5 (62)	3 (65)	4 (254)
Gender, Male/Female [units: Participants]			
Female	0	1	1
Male	12	3	15

Outcome Measures

1. Primary Outcome Measure:

Measure Title	Left Ventricular Ejection Fraction (LVEF), Change From Baseline
Measure Description	To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction.
Time Frame	From the iv loading dose during 30 min and the following maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out

Safety Issue?	Yes
Anticipated Reporting Date	January 2011

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD1305 Dose 1 and Dose 2	AZD1305 was given as an initial intravenous (iv) loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out. The mean total dose of AZD1305 was 30 mg (range 29-31 mg)
Placebo Dose 1 and Dose 2	Sodium chloride was given as an initial iv loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out

Measured Values

	AZD1305 Dose 1 and Dose 2	Placebo Dose 1 and Dose 2
Number of Participants Analyzed	11	4
Left Ventricular Ejection Fraction (LVEF), Change From Baseline [units: Percent change] Mean (95% Confidence Interval)	2.00 (-0.60 to 4.60)	-3.25 (-6.53 to 0.03)

2. Secondary Outcome Measure:

Measure Title	Number of Subjects With at Least One Reported Adverse Event During Each Study Period and in Each Dose Group
Measure Description	To evaluate the tolerability and safety of AZD1305 given as an iv infusion to patients with left ventricular dysfunction.
Time Frame	From randomisation to last study visit (mean infusion time 1.6 hours)
Safety Issue?	Yes
Anticipated Reporting Date	January 2011

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD1305 Dose 1 and Dose 2	AZD1305 was given as an initial intravenous (iv) loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out. The mean total dose of AZD1305 was 30 mg (range 29-31 mg)
Placebo Dose 1 and Dose 2	Sodium chloride was given as an initial iv loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out

Measured Values

	AZD1305 Dose 1 and Dose 2	Placebo Dose 1 and Dose 2
Number of Participants Analyzed	12	4
Number of Subjects With at Least One Reported Adverse Event During Each Study Period and in Each Dose Group [units: Participants]	0	0

3. Secondary Outcome Measure:

Measure Title	Area Under Curve (AUC) (µmol*h/L) of AZD1305
Measure Description	To evaluate the pharmacokinetics of AZD1305, given as an iv infusion, in patients with left ventricular dysfunction
Time Frame	From the iv loading dose during 30 min and the following maintenance iv dose during a maximum of 90 min.
Safety Issue?	Yes
Anticipated Reporting Date	January 2011

Analysis Population Description
[Not Specified]

Reporting Groups

	Description
AZD1305 Dose 1 and Dose 2	AZD1305 was given as an initial intravenous (iv) loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out. The mean total dose of AZD1305 was 30 mg (range 29-31 mg)

	Description
Placebo Dose 1 and Dose 2	Sodium chloride was given as an initial iv loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out

Measured Values

	AZD1305 Dose 1 and Dose 2	Placebo Dose 1 and Dose 2
Number of Participants Analyzed	12	0
Area Under Curve (AUC) (µmol*h/L) of AZD1305 [units: µmol*h/L] Mean (Full Range)	2.04 (1.41 to 2.88)	

4. Secondary Outcome Measure:

Measure Title	QTcF Interval
Measure Description	Maximum QTcF observed for each patient. QTcF is the QT interval corrected for the RR interval using the Fridericia formula
Time Frame	Up to 24 hours following start of IV dosing.
Safety Issue?	Yes
Anticipated Reporting Date	January 2011

Analysis Population Description

[Not Specified]

Reporting Groups

	Description
AZD1305 Dose 1 and Dose 2	AZD1305 was given as an initial intravenous (iv) loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out. The mean total dose of AZD1305 was 30 mg (range 29-31 mg)
Placebo Dose 1 and Dose 2	Sodium chloride was given as an initial iv loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out

Measured Values

	AZD1305 Dose 1 and Dose 2	Placebo Dose 1 and Dose 2
Number of Participants Analyzed	12	4
QTcF Interval [units: ms] Mean (95% Confidence Interval)	446 (409 to 512)	445 (437 to 459)

Reported Adverse Events

Time Frame	[Not specified]
Additional Description	Each patient can experience multiple AEs

Reporting Groups

	Description
AZD1305 Dose 1 and Dose 2	AZD1305 was given as an initial intravenous (iv) loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out. The mean total dose of AZD1305 was 30 mg (range 29-31 mg)
Placebo Dose 1 and Dose 2	Sodium chloride was given as an initial iv loading dose during 30 min followed by a maintenance iv dose during a maximum of 90 min. The infusion was stopped when all echocardiographic measurements had been carried out

Serious Adverse Events

	AZD1305 Dose 1 and Dose 2		Placebo Dose 1 and Dose 2	
	Affected/At Risk (%)	# Events	Affected/At Risk (%)	# Events
Total	0/0		0/0	

Other Adverse Events

Frequency Threshold Above Which Other Adverse Events are Reported: 5%

	AZD1305 Dose 1 and Dose 2		Placebo Dose 1 and Dose 2	
	Affected/At Risk (%)	# Events	Affected/At Risk (%)	# Events
Total	1/12 (8.33%)		1/4 (25%)	
Ear and labyrinth disorders				

	AZD1305 Dose 1 and Dose 2		Placebo Dose 1 and Dose 2	
	Affected/At Risk (%)	# Events	Affected/At Risk (%)	# Events
Vertigo [A] †	1/12 (8.33%)	1	0/4 (0%)	0
Gastrointestinal disorders				
Abdominal Pain Upper [A] †	1/12 (8.33%)	1	0/4 (0%)	0
Diarrhoea [A] †	1/12 (8.33%)	1	0/4 (0%)	0
Flatulence [A] †	1/12 (8.33%)	1	0/4 (0%)	0
Metabolism and nutrition disorders				
Decreased appetite [A] †	1/12 (8.33%)	1	0/4 (0%)	0
Nervous system disorders				
Headache [A] †	1/12 (8.33%)	1	1/4 (25%)	1

† Indicates events were collected by systematic assessment.
A Term from vocabulary, MedDRA 10.0

Limitations and Caveats

[Not specified]

More Information

Certain Agreements:
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:
Name/Official Title: Gerard Lynch
Organization: AstraZeneca
Phone:
Email: aztrial_results_posting@astrazeneca.com